Palpitations and Atrial Fibrillation — on Ibrutinib: When to Act

Not necessarily, and this is not a decision you should make on your own. Your oncologist will assess how severe the AF is, whether it is causing symptoms, and how well it can be controlled with additional medicines. In many cases treatment continues alongside a rate-control drug, or with a short pause and then a dose adjustment. Stopping ibrutinib abruptly without guidance is not a safe response — both your cancer treatment and your heart rhythm need to be weighed against each other by your team, not managed separately.

AF of any cause, including drug-related AF, raises stroke risk because irregular beating allows blood to pool in the heart and clot. Whether you need a blood thinner depends on your individual stroke risk and your bleeding risk together, because ibrutinib also affects platelet function and can increase bleeding. This balance is usually assessed with a cardiologist using a standard scoring tool. Do not start or stop any blood thinner without asking your team first — that decision is more complicated on ibrutinib than for AF in other settings.

Raised blood pressure is a separate, recognised side effect of ibrutinib and can occur independently of any rhythm change, though both can happen at the same time. Both are worth monitoring and reporting. If your readings are noticeably higher than your usual pattern on repeated checks, tell your oncology team. In many cases a blood pressure medicine can be added without needing to stop ibrutinib. Keeping a simple home log — noting the time and which arm — makes it much easier for your team to decide whether and how to act.

A palpitation on its own is a symptom, not a diagnosis. It can come from AF, from a faster-than-normal regular heartbeat, from anxiety, from dehydration, from anaemia, or from other causes. Your team will record an ECG to establish what is actually happening to your heart rhythm. You cannot determine the rhythm from how it feels, and the management of AF is different from the management of other rhythm changes. Do not assume the palpitation is minor or unrelated to ibrutinib without an ECG confirming it.

A home ECG device — the kind held against the chest for thirty seconds — can be useful for capturing a rhythm that comes and goes before you can reach a clinic. Whether it is worth buying depends on how frequently you are having episodes. Ask your oncologist or cardiologist before purchasing, so they can advise which type is compatible with their review systems and how to send them a recording. A reading from a home device supports your team's assessment but does not replace an in-clinic ECG, and it should not delay you from calling when symptoms are concerning.